Sign up to save your podcasts
Or
Share BioVie Inc.
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
BioVie Inc.
100,000 patients in the U.S. have ascites due to advanced liver cirrhosis, with no approved drug to treat ascites. Jonathan Adams, CEO & CFO of BioVie Inc. (OTCQB: BIVI) discusses how the company is developing what they hope to be the first ever approved drug to treat ascites.
View all episodes
By OTC Markets Group
4.2
1010 ratings
100,000 patients in the U.S. have ascites due to advanced liver cirrhosis, with no approved drug to treat ascites. Jonathan Adams, CEO & CFO of BioVie Inc. (OTCQB: BIVI) discusses how the company is developing what they hope to be the first ever approved drug to treat ascites.